There are 2789 resources available
526P - Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Presenter: Pavani Chalasani
Session: ePoster Display
527P - Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)
Presenter: Debashis Sarker
Session: ePoster Display
528P - Discovery of ZN-d5, a potent BCL-2 inhibitor with improved selectivity for BCL-2
Presenter: Joseph Pinchman
Session: ePoster Display
547P - Early pharmacokinetic data from a phase I study of SQ3370 in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform
Presenter: Vivek Subbiah
Session: ePoster Display
548P - Phase I study of oral GZ17-6.02 in patients with advanced solid tumors or lymphoma
Presenter: Alain Mita
Session: ePoster Display
549P - Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)
Presenter: Pavlina Spiliopoulou
Session: ePoster Display
532P - Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours
Presenter: Nicolas Girard
Session: ePoster Display
533P - Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
Presenter: Lyudmila Bazhenova
Session: ePoster Display
534P - Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
Presenter: Alexander Drilon
Session: ePoster Display